A recent phase II clinical trial (NCT03018288) evaluated the safety and antitumor efficacy of combining the peptide vaccine HSPPC-96 with anti-PD-1, pembrolizumab, and chemoradiotherapy in newly diagnosed GBM patients, but no clinical benefits were observed. Here, PDCD1 is linked to glioblastoma.